52 Results

People

  1. Mato
    Mato
  2. Roeker
    Roeker
  3. Zelenetz
    Zelenetz
  4. Thompson
    Thompson
  5. Abdel-Wahab
    Abdel-Wahab
  6. Dorsey
    Dorsey
  7. Geyer
    Geyer
  8. Ghione
    Ghione
  9. Palomba
    Palomba
  10. Goodfriend
    Goodfriend

Groups

  1. Adult Leukemia (52)
  2. Center for Hematologic Malignancies (52)
  3. Department of Medicine (52)
  4. Hematologic Malignancies, Division of (52)
  5. Lymphoma (10)
  6. GME, Medicine (5)
  7. Graduate Medical Education (5)
  8. Hematology-Oncology Fellows (5)
  9. Sloan Kettering Institute Postdocs (5)
  10. Executive Committee, Center for Hematologic Malignancies (4)
  1. "2020"
  2. "Hematologic Malignancies, Division of"
  3. "Anthony Mato"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (14)
  3. Review (4)
  4. Editorial (2)
  5. Research Letter (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Adult Leukemia (52)
  2. Center for Hematologic Malignancies (52)
  3. Department of Medicine (52)
  4. Hematologic Malignancies, Division of (52)
  5. Lymphoma (10)
  6. GME, Medicine (5)

More Groups

People
  1. Anthony Mato (52)
  2. Lindsey Roeker (21)
  3. Andrew Zelenetz (9)
  4. Meghan Thompson (5)
  5. Colleen Dorsey (4)
  6. Maria Palomba (3)

More People

Years
  1. 2020 (52)
Publications
  1. Blood (13)
  2. Leukemia and Lymphoma (11)
  3. Journal of Clinical Oncology (4)
  4. Blood Advances (2)
  5. British Journal of Haematology (2)
  6. Clinical Advances in Hematology & Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (17)
  2. Taylor & Francis Group (11)
  3. American Society of Clinical Oncology (4)
  4. American Association for Cancer Research (3)
  5. Dove Medical Press Ltd (2)
  6. Elsevier Inc. (2)

More Publishers

Results (52)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax effectiveness, safety, and treatment patterns in chronic lymphocytic leukemia patients: Results from the CLL collaborative study of real-world evidence (CORE)
    Meeting Abstract

    Zheng, D.; Sail, K.; Roeker, L. E.; Manzoor, B. S.; Tuncer, H. H.; Allan, J. N.; Ujjani, C. S.; Barr, P. M.; Brown, J. R.; Eyre, T. A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, waldenstrom's macroglobulinemia, and other non-hodgkin lymphomas: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T. S.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase 1 and dose expansion study of APR-246 in combination with ibrutinib or venetoclax-based therapy in subjects with TP53-mutant relapsed and/or refractory non-hodgkin lymphomas (NHL) including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
    Meeting Abstract

    Thompson, M. C.; Davids, M. S.; Jain, N.; Soumerai, J. D.; Geethakumari, P. R.; Gubits, A.; Hickman, D.; Wennborg, A.; Attar, E. C.; Abdel-Wahab, O.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Venetoclax re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen
    Meeting Abstract

    Thompson, M. C.; Allan, J. N.; Sail, K.; Manzoor, B. S.; Pu, J. J.; Barr, P. M.; Coombs, C. C.; Schuster, S. J.; Skarbnik, A.; Rhodes, J. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Worldwide examination of patients with CLL hospitalized for COVID-19
    Meeting Abstract

    Roeker, L. E.; Scarfo, L.; Chatzikonstantinou, T.; Abrisqueta, P.; Eyre, T. A.; Cordoba, R.; Prat, A. M.; Villacampa, G.; Leslie, L. A.; Koropsak, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Marańda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory Richter's transformation and de novo diffuse large B-cell lymphoma
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Foss, F. M.; Isufi, I.; Kothari, S. K.; Ding, W.; Brander, D. M.; Sitlinger, A.; Rosenthal, A. C.; Leis, J. F.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Real-world prognostic biomarker testing, treatment patterns and dosing among 1461 Patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the informCLL prospective observational registry
    Meeting Abstract

    Mato, A. R.; Barrientos, J. C.; Sharman, J. P.; Brander, D. M.; Gutierrez, M.; Kadish, K.; Arango-Hisijara, I.; Upasani, S.; Han, J.; Huang, Q.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation
    Meeting Abstract

    Mato, A.; Tang, B.; Azmi, S.; Yang, K. R.; Stern, J. C.; Hedrick, E.; Huang, J.; Sharman, J. P.
    Blood (2020)

    Fulltext@MSK | Save
  • COVID-19 impact on lymphoma patients' clinical outcomes - An observational cohort study
    Meeting Abstract

    Ip, A.; Mato, A.; Intrator, J.; Howard, N. P.; Petrillo, A.; Vicioso, R.; Sebti, R.; Cicogna, C.; Magarelli, G.; Leslie, L. A.; more...
    Blood (2020)

    Fulltext@MSK | Save